| Message: | Targeting checkpoint inhibitors using monoclonal antibodies results in significantly successful outcome of cancer patients compared to conventional chemotherapy. Recently, indoleamine (2,3)-dioxygenase (IDO) was identified as a novel checkpoint protein involved in generating the immunosuppressive tumor microenvironment that supports tumor growth. IDO inhibitors have been well-developed and have shown promising antitumor activity in early clinical trials, and seem to be synergistic in combination with chemotherapy and other forms of immunotherapy. Creative Biolabs has successfully established an optimized Magic™ “humanized” animal platform to offer specialty manipulated IDO immune checkpoint knock-in mice for our clients all over the world. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-ido-immune-checkpoint-knock-in-mice.htm. |
my account
